ImmunoGen, Inc. Announces Presentations at the 22nd ImmunoGen, Inc.-European Organization for Research and Treatment of Cancer-National Cancer Institute Symposium on Molecular Targets and Cancer Therapeutics

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.
MORE ON THIS TOPIC